[Assessment of respiratory function in patients with chronic obstructive pulmonary diseases treated with budesonide].
The aim of the study was to carry out assessment of the respiratory function of patients with COPD undergoing a three month (600 microgram) treatment with an inhaled steroid--Budesonide. This was a double blind study carried out on 57 patients. During treatment with Budesonide a clinical improvement was seen. Respiratory function parameters did not alter throughout the 3 month treatment period, although bronchial reactivity diminished. Side effects were seen only in 3 patients--in all it was dysphonia. It seems that Budesonide can be added to other treatment protocols in patients with exacerbations of chronic bronchitis.
Kozak-Szkopek
E
E
Katedry i Kliniki Chorób Wewnetrznych, Akademii Medycznej w Lublinie.
D000280:Administration, Inhalation; D000328:Adult; D000336:Aerosols / Q000494:pharmacology / Q000627:therapeutic use*; D000368:Aged; D001993:Bronchodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019819:Budesonide; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011282:Pregnenediones / Q000494:pharmacology / Q000627:therapeutic use*; D015656:Respiratory Mechanics / Q000187:drug effects; D014832:Voice Disorders / Q000139:chemically induced
D000336:Aerosols; D001993:Bronchodilator Agents; D011282:Pregnenediones; D019819:Budesonide